Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 21, 2024
Distillery Therapeutics

Increasing Kupffer cell GPR3 activation for obesity

BioCentury | Aug 30, 2023
Regulation

Aug. 30 Quick Takes: With Embark acquisition, Novo gains another obesity asset

Plus: Epigenome editing company Epigenic raises $32M series A and updates from Outlook, InflaRx, Zealand and FDA
BioCentury | Nov 19, 2015
Distillery Therapeutics

Therapeutics: G protein-coupled receptor 3 (GPR3)

BioCentury | Dec 13, 2012
Distillery Therapeutics

Indication: Neurology

BioCentury | Dec 6, 2012
Targets & Mechanisms

Thinking outside the amyloid box

BioCentury | Sep 16, 2010
Targets & Mechanisms

Introducing GSAP

BioCentury | Aug 23, 2010
Product Development

Gamma no-go

Safety problems for Eli Lilly Alzheimer's drug argue for new approaches to target
BioCentury | Feb 26, 2009
Distillery Therapeutics

Indication: Neurology

Items per page:
1 - 8 of 8